Fig. 5

Demethylation suppressed the development of renal cancer by activating RUNX3 and TGF-β. a Global and CpG methylation levels of RUNX3 and TGF-β in metastatic xenograft cancer model inoculated with 5-aza-2′-deoxycytidine (10 mM) treated metastatic cancer cells were detected by using quantitative methylation real-time PCR and qMSP compared with non-treated metastatic xenograft models (*p < 0.05, **p < 0.01). The data were mean ± SD of three independent experiments. b RUNX3 and TGF-β expression with treatment of 5-aza-2′-deoxycytidine were detected in metastasis renal xenograft cancer model by Western blot. Relative expression values represent mean ± SD from three independent experiments (**p < 0.01). Quantitation by densitometry is also shown. c The xenograft metastatic models with or without 5-aza-2′-deoxycytidine treatment was established after injection of 1 × 10⁴ different cells in the left foreleg, respectively. The survival periods were calculated after each mouse was dead (n = 10). d Tumor volumes were measured in xenografts from renal metastatic cancer cells with or without 5-aza-2′-deoxycytidine treatment 2 months post inoculation when mice were still alive but sick. Values are mean ± SD from at least three independent experiments (**p < 0.01)